Pgnx stock analysis

NASDAQ:PGNX Progenics Pharmaceuticals, Inc. Stock Analysis ...

stoxline.com provides: stock quote, technical analysis, fundamental analysis, stock rating, stock news PGNX - Progenics Pharmaceuticals News - Barchart.com Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar. Progenics Pharmaceuticals, Inc. Stock (PGNX): Technical ... PGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average. PGNX Stock Rating and Data | Progenics Pharmaceuticals ...

Progenics Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. PGNX updated stock price target summary. Dow Jones, a News Corp company.

PGNX | Stock Snapshot - Fidelity Apr 01, 2020 · Stock quote and company snapshot for PROGENICS PHARMACEUTICALS INC (PGNX), including profile, stock chart, recent news and events, analyst opinions, and research reports. PGNX Progenics Pharmaceuticals Inc. — Stock Price and ... Real-time trade and investing ideas on Progenics Pharmaceuticals Inc. PGNX from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. $PGNX Stock Technical Analysis | Progenics | SwingTradeBot.com

PGNX Price Target and Analyst Ratings (Progenics ...

View Progenics Pharmaceuticals Inc. PGNX investment & stock information. Get the latest Progenics Pharmaceuticals Inc. PGNX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Progenics Pharmaceuticals Inc. Common Stock (PGNX) Analyst ... Mar 27, 2020 · Find the latest analyst research for Progenics Pharmaceuticals Inc. Common Stock (PGNX) at Nasdaq.com.

Real-time trade and investing ideas on Progenics Pharmaceuticals Inc. PGNX from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal.

PGNX Stock News - Fidelity Apr 02, 2020 · Lantheus Holdings, Inc. (LNTH), parent company of Lantheus Medical Imaging, Inc., a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have … Progenics Pharmaceuticals Inc. Stock Price (PGNX) | Barron's View today's stock price, news and analysis for Progenics Pharmaceuticals Inc. (PGNX). Barron's also provides information on historical stock ratings, target prices, company earnings, market

In-depth view of key statistics and finances for PROGENICS PHARMACEUTICALS, INC. (PGNX) on MSN Money.

View today's stock price, news and analysis for Progenics Pharmaceuticals Inc. ( PGNX). Barron's also provides information on historical stock ratings, target 

Apr 02, 2020 · Lantheus Holdings, Inc. (LNTH), parent company of Lantheus Medical Imaging, Inc., a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have … Progenics Pharmaceuticals Inc. Stock Price (PGNX) | Barron's View today's stock price, news and analysis for Progenics Pharmaceuticals Inc. (PGNX). Barron's also provides information on historical stock ratings, target prices, company earnings, market PGNX Price Target and Analyst Ratings (Progenics ... Nov 05, 2019 · Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 300.00%. The high price target for PGNX is $14.00 and the low price target for PGNX is $10.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy." Progenics Pharmaceuticals (NasdaqGS:PGNX) - Share price ... It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York. Show less